newsfilter
← Latest News
Business Wire·

Kiromic BioPharma Reports Favorable Early Efficacy Results from First Patient in Deltacel-01 Phase 1 Clinical Trial in Non-Small Cell Lung Cancer

Stabilization of Disease Observed at Six Weeks, Therapy Continues to Be Well Tolerated Kiromic BioPharma, Inc. (OTCQB:KRBP) ("Kiromic" or the "Company") reports favorable early efficacy results from the first patient